We are a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases.
Scroll down to discover
At OncoDNA, we are a group of passionate people who are bound and led by the desire of revolutionizing the way patients diagnosed with a cancer or a genetic disease are treated. Our ultimate mission is to be able to improve all patients’ health by empowering physicians, biopharma companies and researchers to deliver the promise of precision medicine.
With the development of next-generation sequencing technologies, our understanding of the human genome has improved signficantly, leading to a cascade of scientific discoveries and new treatments. Yet, we are still a long way off from finding a universal treatment for genetic diseases such as cancer. At OncoDNA, we believe that we all need to come together and join our forces. Through collaboration, we can have a greater impact on patient care.
In our relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain - from translational research and drug development to patient treatment, monitoring and reimbursement. We deeply value these interactions and we are committed to actively listening to every need and putting the right resources to achieve our mission.
Jean-Pol DETIFFE, Founder of OncoDNA
Better understanding the behavior and molecular characteristics of a disease is key to improve patient journey and clinical outcome. At OncoDNA, we are specializing in the genomics and theranostics of cancer and genetic diseases. This enables us not only to bring the molecular insights that researchers, biopharma companies and clinicians need, but also to facilitate the analysis and clinical interpretation of those complex data.
We strongly believe that empowering our employees and partners is key to stay ahead of the science. The field of genomics is advancing fast. Thanks to our flexibility, entrepreneurial mindset and highly competent teams, we have been able to develop a complete portfolio of genomic services, biomarker tests and bioinformatics solutions to support the translation of precision medicine from bench to bedside. Over the years, our solutions have helped deliver breakthrough, accelerate drug development, and bring therapeutic innovation into routine care.
Bernard COURTIEU, CEO of OncoDNA
OncoDNA was born in 2012 from the idea of making precision medicine a reality in oncology. Next-generation sequencing was in its early days. Combined with other technologies, NGS had the power to personalize cancer care and bring the right treatment at the right patient at the right time. In just a decade, we have grown into a renown company that drives innovation in research, accelerates drug development and has helped thousands of patients globally. Today, OncoDNA comprises two entities - BioSequence and IntegraGen - and employs approx. 115 employees in 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories.
2012
Foundation of OncoDNA by Jean-Pol Detiffe, an entrepreneurial pharmacist who had previously created the DNA sequencing pioneering firm DNAvision. The OncoDNA startup sets grounds in Gosselies, Belgium, and counts a small team of 5 employees.
2014
First steps in the molecular profiling of advanced solid cancer with OncoDEEP, the first comprehensive biomarker test that screens a tumor tissue and helps oncologists match the molecular characteristics of the tumor with the most relevant treatment options for a patient.
2015
Launch of OncoSHARE, a secure online platform that gives access to the clinical recommendations resulting from OncoDNA biomarker tests from the world over.
2016
Specialization in liquid biopsy with the launch of the very first personalized liquid biopsy test available on the market. The test screens the circulating tumor DNA present in blood samples in order to predict sensitivity/resistance to targeted therapies, monitor disease progression or detect early relapse.
2017
Global commercialization of OncoKDM, our NGS data interpretation platform, as Software as a Service. Clinical laboratories, pathologists, biologists who run their own genetic tests can now benefit from our knowledge database and clinical interpretation.
2017
OncoDNA acquires Spanish personalized cancer genomics firm BioSequence as part of an effort to expand its presence in Europe and Latin America.
2018
First collaboration with a biopharma company. OncoDNA supports patient enrollment to Kura Oncology's phase II trial of tipifarnib.
2020
OncoDNA acquires the French genomics firm IntegraGen. The combination of both companies will make it possible to offer a unique range of services that combine extensive lab testing, bioinformatics, production and data interpretation capabilities for clinical and research applications in oncology and genetic diseases.
2021
OncoDNA revolutionizes cancer care by enabling the production of personalized vaccines for patients who have run out of treatment options in collaboration with the Belgium-based company myNEO.
Christine was diagnosed in 2017 with uterus cancer. Our molecular profiling report annotated that Christine would not react positively to Dacarbazine but only to Doxorubicin. Thus avoiding her some adverse drug reactions.
"From that time, getting the results, my whole life changed, I hope again. I saw my life completely differently, I wanted to live, I wanted to fight this cancer. And why would I not be cured? "
"I have 100% faith again and I think it's thanks to all this: Dr Mouysset, the journey I've been on personally, what you do, the innovations you set up !"
"I have recommended these tests to many people that are in the same situation as I was, hoping that they will also find a solution"